BID | 88.54 | ASK | 354.14 | ||
Open | 220.78 | Previous Close | 219.83 | ||
Pre-Market | - | After-Market | 221.25 | ||
- - | - -% |
Target Price | 272.13 | Analyst Rating | Moderate Buy 2.50 | |
Potential % | 23.00 | Finscreener Ranking | + 38.27 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-87 | Value Ranking | ★ 40.54 | |
Insiders Value % 3/6/12 mo. | -100/-100/-98 | Growth Ranking | ★★★+ 53.51 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-98 | Income Ranking | ★ 31.46 | |
Price Range Ratio 52W % | 44.15 | Earnings Rating | Sell | |
Market Cap | 10.40B | Earnings Date | 2nd Nov 2023 | |
Alpha | -0.01 | Standard Deviation | 0.09 | |
Beta | 1.04 |
Today's Price Range 219.64224.35 | 52W Range 177.63276.43 | 5 Year PE Ratio Range 22.6088.30 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 0.74% | ||
1 Month | 22.54% | ||
3 Months | 0.99% | ||
6 Months | -5.39% | ||
1 Year | -2.79% | ||
3 Years | -40.75% | ||
5 Years | -19.03% | ||
10 Years | 128.91% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 9.05 | |||
ROE last 12 Months | 11.80 | |||
ROA (5Y Avg) | 3.65 | |||
ROA last 12 Months | 6.49 | |||
ROC (5Y Avg) | 6.35 | |||
ROC last 12 Months | 7.85 | |||
Return on invested Capital Q | 1.99 | |||
Return on invested Capital Y | 2.40 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 5.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
29.60 | ||||
3.11 | ||||
5.93 | ||||
27.40 | ||||
94.10 | ||||
9.41 | ||||
-17.37 | ||||
83.04 | ||||
13.51B | ||||
Forward PE | 15.72 | |||
PEG | 4.23 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.30 | ||||
2.40 | ||||
0.30 | ||||
0.46 | ||||
11.20 | ||||
Leverage Ratio | 1.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
54.70 | ||||
18.90 | ||||
27.10 | ||||
13.60 | ||||
14.00 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.03B | ||||
43.34 | ||||
3.58 | ||||
6.67 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.53 | ||||
1.36 | ||||
0.00 | ||||
0.00 | ||||
Payout ratio | 23.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | 3.27 | 3.64 | 11.31 |
Q02 2023 | 3.21 | 3.41 | 6.23 |
Q01 2023 | 2.97 | 3.09 | 4.04 |
Q04 2022 | 3.44 | 3.52 | 2.33 |
Q03 2022 | 3.10 | 3.27 | 5.48 |
Q02 2022 | 3.35 | 3.39 | 1.19 |
Q01 2022 | 2.73 | 2.88 | 5.49 |
Q04 2021 | 3.53 | 3.60 | 1.98 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | 3.36 | -4.00 | Negative |
12/2023 FY | 13.38 | 0.68 | Positive |
3/2024 QR | 3.19 | -2.45 | Negative |
12/2024 FY | 13.99 | -2.37 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 3.27 |
Estimates Count | 15 |
EPS Growth Next 5 Years % | 7.00 |
Volume Overview | |
---|---|
Volume | 341.80K |
Shares Outstanding | 46.99K |
Shares Float | 46.33M |
Trades Count | 12.05K |
Dollar Volume | 75.98M |
Avg. Volume | 273.67K |
Avg. Weekly Volume | 173.77K |
Avg. Monthly Volume | 340.63K |
Avg. Quarterly Volume | 306.59K |
Teleflex Incorporated (NYSE: TFX) stock closed at 219.83 per share at the end of the most recent trading day (a 0.45% change compared to the prior day closing price) with a volume of 315.23K shares and market capitalization of 10.40B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 14000 people. Teleflex Incorporated CEO is Liam J. Kelly.
The one-year performance of Teleflex Incorporated stock is -2.79%, while year-to-date (YTD) performance is -11.94%. TFX stock has a five-year performance of -19.03%. Its 52-week range is between 177.633 and 276.43, which gives TFX stock a 52-week price range ratio of 44.15%
Teleflex Incorporated currently has a PE ratio of 29.60, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of 5.93, a price to cashflow ratio of 27.40, a PEG ratio of 4.23, a ROA of 6.49%, a ROC of 7.85% and a ROE of 11.80%. The company’s profit margin is 14.00%, its EBITDA margin is 27.10%, and its revenue ttm is $2.03 Billion , which makes it $43.34 revenue per share.
Of the last four earnings reports from Teleflex Incorporated, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.27 for the next earnings report. Teleflex Incorporated’s next earnings report date is -.
The consensus rating of Wall Street analysts for Teleflex Incorporated is Moderate Buy (2.5), with a target price of $272.13, which is +23.00% compared to the current price. The earnings rating for Teleflex Incorporated stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Teleflex Incorporated has a dividend yield of 0.53% with a dividend per share of $1.36 and a payout ratio of 23.00%.
Teleflex Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 7.90, ATR14 : 5.34, CCI20 : 90.46, Chaikin Money Flow : 0.21, MACD : 6.26, Money Flow Index : 53.28, ROC : 9.65, RSI : 67.41, STOCH (14,3) : 94.90, STOCH RSI : 0.82, UO : 58.48, Williams %R : -5.10), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Teleflex Incorporated in the last 12-months were: Liam J. Kelly (Option Excercise at a value of $4 108 319), Liam J. Kelly (Sold 32 686 shares of value $8 172 486 ), Randle Stuart (Option Excercise at a value of $305 484), Randle Stuart (Sold 3 021 shares of value $742 290 ), Stephen K. Klasko (Option Excercise at a value of $236 599), Stephen Klasko (Option Excercise at a value of $236 599)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (26% of 2020 sales), interventional (15%), surgical (13%), anesthesia (12%), interventional urology (13%), original-equipment manufacturing (7%), and all other (14%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.
CEO: Liam J. Kelly
Telephone: +1 610 225-6800
Address: 550 East Swedesford Road, Wayne 19087, PA, US
Number of employees: 14 000
Wed, 26 Jul 2023 14:35 GMT Teleflex (TFX) Gets a Buy from JMP Securities
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.